ASCO publishes a suite of peer-reviewed journals with content focused on

  • clinical oncology research;
  • issues and insights affecting oncology practice;
  • cancer care, research, and care delivery issues unique to countries and settings with limited healthcare resources;
  • biomedical informatics methods and processes applied to cancer-related data, information, and images; and
  • the science and practice of precision oncology.

ASCO’s peer-reviewed journals follow a continuous publication schedule. Below is a select list of the newest content from ASCO’s journals. ASCO will update the list on a near-daily basis, and we encourage you to check this page frequently. Email ASCO’s Media Team to request an embargoed journal article or an interview with a study author.

ASCO occasionally highlights select journal articles in an embargoed press release known as a News Digest or in a Featured Article summary. Sign up to receive communications regarding these articles.
 

Publishing February 1, 2022, 4:00 pm ET:

Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes (Original Report)
Steven A. Rosenberg, et al. 
Request article

The Incidence, Nature, and Consequences of Oncologists' Experiences with Sexual Harassment (Original Report)
Reshma Jagsi, et al.
Request article

Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer: A Multicenter, Single-arm, Phase 2 Trial (Original Report)
Samuel Aaron Funt, et al.
Request article

Published January 27, 2022, 4:00 pm ET:

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery For Resectable And Borderline Resectable Pancreatic Cancer: Long-term Results Of The Dutch Randomized PREOPANC Trial (Original Report)
Eva Versteijne, et al. 
Request article

FDA Approval Summary: Abemaciclib with Endocrine Therapy for High-Risk Early Breast Cancer (Rapid Communications)
Melanie E Royce, et al.
Request article

Elevated Coronary Artery Calcium Quantified by a Validated Deep Learning Model From Lung Cancer Radiotherapy Planning Scans Predicts Mortality (Original Report)
Katelyn Mae Atkins, et al.
Request article

Translating Research to Action: The Development of a Pediatric Palliative Cancer Care Advocacy Tool in Eurasia (Special Article)
Bella Ehrlich, et al.
Request article

Urinary 3-methoxytyramine is a biomarker for MYC activity in patients with neuroblastoma (Original Report)
Yvette Matser, et al.
Request article

Efficacy and Safety of Larotrectinib in Patients with TRK Fusion-Positive Lung Cancers (Original Report)
Alexander Drilon, et al.
Request article

Improved gene fusion detection in childhood cancer diagnostics using RNA sequencing (Original Report)
Jayne Hehir, et al.
Request article

Published January 25, 2022, 4:00 pm ET:

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants (Original Report)
Antonis Antoniou, et al. 
Request article

Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With ABVD and Limited-Field Radiotherapy (Original Report)
Ingemar Bengt Lagerlöf, et al. 
Request article

Interpreting ORATOR: Lessons Learned From a Randomized Comparison of Primary Surgical and Radiation Approaches for Early-Stage Oropharyngeal Cancer  (Editorial)
Joseph Kamel Salama, et al. 
Request article

Human Papillomavirus Infection Determines Prognosis in Cervical Cancer (Original Report)
Karin Sundström, et al. 
Request article

Response-Adapted Therapy in Follicular Lymphoma: At the Threshold of a Precision Approach (Editorial)
Carla Casulo, et al. 
Request article

Published January 24, 2022, 4:00 pm ET:

HER2-Mutant Non-Small Cell Lung Cancer: Continued Progress but Challenges Remain (Editorial)
Justin Gainor, et al. 
Request article

Combination of Trastuzumab, Pertuzumab and Docetaxel in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Harboring HER2 Mutations : Results From The IFCT-1703 R2D2 Trial (Original Report)
Julien Mazieres, et al. 
Request article

First Extensive Analysis of 18F-FDG PET-CT in a Large Cohort of Patients With HIV-Associated Hodgkin Lymphoma: Baseline Total Metabolic Tumor Volume Impacts Prognosis (Original Report)
Laetitia Vercellino, et al. 
Request article

Keeping a Safe Distance from Surgical Volume Standards (Editorial)
Benjamin Kozower, et al. 
Request article

Published January 21, 2022, 4:00 pm ET:

Development and Validation of a Predictive Model of Severe Fatigue after Breast Cancer: Towards a Personalized Framework in Survivorship Care (Original Report)
Ines Maria Vaz Duarte Luis, et al. 
Request article

Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial (Original Report) 
Laura J. van ’t Veer, et al. 
Request article

Health Literacy and Clinical Outcomes Following Hematopoietic Stem-Cell Transplantation (Original Contribution)
Natalie Bezler, et al. 
Request article

Association of Organizational Context, Collaborative Practice Models, and Burnout Among Physician Assistants in Oncology (Original Contribution)
Eric Tetzlaff, et al. 
Request article

Published January 20, 2022, 4:00 pm ET:

APOBEC-Induced Protein Changes in ER-Positive, HER2-Negative Breast Cancer Throughout Disease Progression (Original Report)
Manouk Bos, et al.
Request article

Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort (Original Report)
Michael Hassett, et al.
Request article

ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-HER2 Therapy in Advanced Gastroesophageal Adenocarcinoma (Original Report)
Alexa Betzig Schrock, et al.
Request article

Published January 19, 2022, 4:00 pm ET:

H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With HBV, HCV, or Dual HBV–HCV Infection (Original Report)
Chi Ching Chang, et al.
Request article

Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies (Original Report) 
Cari Kitahara, et al.
Request article

CALGB 40603 (Alliance): Long-term Outcomes and Genomic Correlates of Response and Survival after Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer (Original Report) 
Jonathan Shepherd, et al.
Request article

Paclitaxel and Carboplatin for Uterine Carcinosarcoma: A Path to Inclusion (Editorial)
Daniela Matei, et al.
Request article

TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma (Original Report) 
Tina Nielsen, et al. 
Request article

Competencies for Nurses Regarding Psychosocial Care of Patients With Cancer in Africa: An Imperative for Action (Special Article)
Margaret Fitch, et al. 
Request article

Published January 18, 2022, 4:00 pm ET:

Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naïve Advanced Gastrointestinal Stromal Tumor (GIST) (ASCO Special Article)
Ping Chi, et al. 
Request article

The embargo date and time of a journal article coincide with its online publication date and time. Journalists may conduct embargoed interviews with study authors up to one week prior to the online publication date. ASCO takes embargo violations seriously and violations typically result in the loss of journal media privileges for a period of one year and may affect broader ASCO media privileges as well. Journalists may request embargoed articles. Please direct further questions regarding the embargo policies for ASCO Journals to the Media Team.